Donanemab showed about 40% less decline in daily task performance compared to a placebo, making it highly effective for Alzheimer's patients.
Collection
[
|
...
]
Donanemab showed about 40% less decline in daily task performance compared to a placebo, making it highly effective for Alzheimer's patients.